Communiqués Alkermes plc

Actions

ALKS

IE00B56GVS15

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/09/2026			Varia. 5j.	Varia. 1 janv.
44,18 ^USD	+1,82%		-3,60%	+57,90%

21/09	Alkermes Plc annonce des résultats de phase 1b positifs démontrant la preuve de concept clinique de l'ALKS 7290 chez les adultes souffrant de trouble du déficit de l'attention avec hyperactivité	CI
21/09	Alkermes : des résultats prometteurs en Phase 1b pour son candidat-médicament contre le TDAH ; le titre grimpe en avant-Bourse	MT

Communiqués

21/09	Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)	BU
16/09	Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors	BU
10/09	Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards(R) Program	AQ
10/09	Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program	BU
25/08	The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1	BU
28/07	Alkermes plc Reports Second Quarter 2026 Financial Results	BU
16/07	Alkermes to Report Second Quarter Financial Results on July 28, 2026	AQ
14/07	Alkermes to Report Second Quarter Financial Results on July 28, 2026	BU
13/07	Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis	BU
17/06	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026	BU
15/06	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe	BU
05/06	Alkermes to Present New Data on Alixorexton and LUMRYZ at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research	AQ
04/06	Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research	BU
03/06	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
26/05	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting	BU
21/05	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences	BU
12/05	Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia	BU
06/05	Alkermes : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Alkermes : ALKS Q1 2026 Earnings Call Prepared Remarks FINAL	PU
05/05	Alkermes : Q1 2026 Financial Results Press Release v2	PU
05/05	Alkermes : ALKS Q1 2026 Earnings Slides FINAL	PU
05/05	Alkermes: Q1 Earnings Snapshot	AQ
05/05	Alkermes plc Reports First Quarter 2026 Financial Results	BU
21/04	Alkermes to Report First Quarter Financial Results on May 5, 2026	BU
16/04	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting	BU